|Table of Contents|

An improved method and the preliminary application research for the preparation of organoids from tumor patients

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

Issue:
2023 02
Page:
222-227
Research Field:
Publishing date:

Info

Title:
An improved method and the preliminary application research for the preparation of organoids from tumor patients
Author(s):
ZHANG Qian1; CHEN Meiqi2; 3; WANG Juan2; 3
1.Affiliated Hospital of Medical Sergeant School,Army Medical University,Hebei Shijiazhuang 050000,China;2.Pharmacological Evaluation Research Center of Shanghai Pharmaceutical Industry Research Institute,Shanghai 200437,China；3.State Key Laboratory of New Drug and Pharmaceutical Process,Shanghai Pharmaceutical Industry Research Institute Co.,Ltd.,Shanghai 200437,China.
Keywords:
PDO model; tumor; improved method
PACS:
R73-3
DOI:
10.3969/j.issn.1672-4992.2023.02.005
Abstract:
Objective:To construct the platform of patient derived organs (PDO) and compare the success rate of the model between the traditional method and the improved method.Methods:The classic PDO model of tumor was established,and the improved PDO model was established after modifying the conditions such as mechanical crushing degree,digestion time and temperature.The difference between PDO and original tumor samples was evaluated by HE staining.Results:PDO was successfully established in 59 cases,covering 17 tumor types.The results of HE staining showed that PDO from patients was highly similar to the original tumors in morphology and proliferative expression.After optimization,the extraction rate of PDO cells was significantly improved,and the growth condition was satisfactory.Conclusion:PDO keeps the similar characteristics with its parents.The success rate of PDO model of the improved method is significantly higher than that of the traditional method.

References:

［1］JEMAL A,BRAY F,CENTER MM,et al.Global cancer statistics ［J］.CA:A Cancer Journal for Clinicians,2011,61(2):69-90.
［2］ZHENG WL,ZHANG H,SHEN CF,et al.Trend analysis of lung cancer mortality and years of life lost (YLL) rate from 1999 to 2016 in Tianjin,China:Does the lung cancer burden in rural areas exceed that of urban areas ［J］.Thoracic Cancer,2020,11(4):867-874.
［3］邹小农,赵平.中国癌症态势七十年分析［J］.中国肿瘤临床与康复,2019,26(10):1153-1161. ZOU XN,ZHAO P.Seventy years of cancer trends in China ［J］.Chinese Journal of Clinical Oncology and Rehabilitation,2019,26(10):1153-1161.
［4］李红丽.60岁及以上城市居民主要慢性病死亡率的时间趋势［J］.中国老年学杂志,2019,39(13):3300-3303. LI HL.Temporal trends of mortality from major chronic diseases in urban residents aged 60 and over ［J］.Chinese Journal of Gerontology,2019,39(13):3300-3303.
［5］韩苏军,王栋,寿建忠,等.跨世纪十年中国肾癌死亡趋势分析［J］.癌症进展,2019,17(10):1143-1146. HAN SJ,WANG D,SHOU JZ,et al.Analysis of the trend of death of kidney cancer in China in the past ten years ［J］.Oncology Progress,2019,17(10):1143-1146.
［6］BARRETINA J,CAPONIGRO G,STRANSKY N,et al.The cancer cell line encyclopedia enables predictive modelling of anticancer drug sensitivity ［J］.Nature,2012,483(7391):603-607.
［7］VYAS D,BAPTISTA PM,BROVOLD M,et al.Self-assembled liver organoids recapitulate hepatobiliary organogenesis in vitro ［J］.Hepatology,2018,67(2):750-761.
［8］SANTO VE,REBELO SP,ESTRADA MF,et al.Drug screening in 3D in vitro tumor models:overcoming current pitfalls of efficacy read-outs［J］.Biotechnology Journal,2017,12(1):1-18.
［9］LANGHANS SA.Three-dimensional in vitro cell culture models in drug discovery and drug repositioning ［J］.Frontiers in Pharmacology,2018,9(6):1-14.
［10］VILLASANTE A,VUNJAK-NOVAKOVIC G.Tissue-engineered models of human tumors for cancer research ［J］.Expert Opinion on Drug Discovery,2015,10(3):257-268.
［11］KONDO J,ENDO H,OKUYAMA H,et al.Retaining cell-cell contact enables preparation and culture of spheroids composed of pure primary cancer cells from colorectal cancer ［J］.Proceedings of the National Academy of Sciences of the United States of America,2011,108(15):6235-6240.
［12］KONDO J,EKAWA T,ENDO H,et al.High-throughput screening in colorectal cancer tissue-originated spheroids ［J］.Cancer Science,2019,110(1):345-355.
［13］DING L,ELLIS MJ,LI S,et al.Genome remodelling in a basal-like breast cancer metastasis and xenograft ［J］.Nature,2010,464(7291):999-1005.
［14］DEROSE YS,WANG G,LIN YC,et al.Tumor grafts derived from women with breast cancer authentically reflect tumor pathology,growth,metastasis and disease outcomes ［J］.Nature Medicine,2011,17(11):1514-1520.
［15］JULIEN S,MERINO-TRIGO A,LACROIX L,et al.Characterization of a large panel of patient-derived tumor xenografts representing the clinical heterogeneity of human colorectal cancer ［J］.Clinical Cancer Research,2012,18(19):5314-5328.
［16］BASILE D,SIMIONATO F,CAPPETTA A,et al.State-of-the-art of monoclonal antibodies for the treatment of gastric cancer ［J］.Biologics,2021,15(12):451-462.
［17］KAWAI S,NAKANO K,TAMAI K,et al.Generation of a lung squamous cell carcinoma three-dimensional culture model with keratinizing structures ［J］.Scientifc Reports,2021,11(1):1-12.
［18］VLACHOGIANNIS G,HEDAYAT S,VATSIOU A,et al.Patient-derived organoids model treatment response of metastatic gastrointestinal cancers ［J］.Science,2018,359(6378):920-926.
［19］SACHS N,CLEVERS H.Organoid cultures for the analysis of cancer phenotypes ［J］.Curr Opin Genet Dev,2014,24(2):68-73.
［20］ YAO Y,XU X,YANG L,et al.Patient-derived organoids predict chemoradiation responses of locally advanced rectal cancer ［J］.Cell Stem Cell,2020，26(1):17-26.

Memo

Memo:
-
Last Update: 1900-01-01